72 Investment Holdings, LLC
Long book
$49.6M
Q1 2026
Positions
5
Top-10 weight
100%
concentration
Last quarter
-2.7%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filings72 Investment Holdings, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $49.6M US long book across 5 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: PRAXIS PRECISION MEDICINES I, ALTO NEUROSCIENCE INC, LENZ THERAPEUTICS INC, KORRO BIO INC, CARIBOU BIOSCIENCES INC.
Over the last 9 quarters its long book ran on average 2.8pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-41.5%
Q2 2024
+21.7%
Q3 2024
+6.1%
Q4 2024
-27.2%
Q1 2025
+7.8%
Q2 2025
+78.2%
Q3 2025
-25.6%
Q4 2025
-1.9%
Q1 2026
-2.7%
Sector allocation
Healthcare 100%
Long book by quarter
What does 72 Investment own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 65.9K | $21.2M | 42.8% | Held |
| ANRO ALTO NEUROSCIENCE INC | Healthcare | 667.8K | $15.0M | 30.3% | Held |
| LENZ LENZ THERAPEUTICS INC | Healthcare | 1.0M | $9.3M | 18.8% | Held |
| KRRO KORRO BIO INC | Healthcare | 276.8K | $3.1M | 6.3% | Held |
| CRBU CARIBOU BIOSCIENCES INC | Healthcare | 474.1K | $901K | 1.8% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 5 | $49.6M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 5 | $50.6M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 5 | $67.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 6 | $38.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 6 | $35.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 7 | $49.1M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 7 | $46.5M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 7 | $39.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 7 | $67.1M | canonical | SEC ↗ |